The reductions in total cholesterol, LDL cholesterol and triglycerides levels, together with a robust decrease in ALT and AST levels, confer comprehensive metabolic benefits to patients with obesity or type 2 diabetes and supported a further investigation and development of IBI362 in non-alcoholic steatosis hepatitis. The gene discussed is GPT; the disease is type 2 diabetes mellitus.